Pedro Enrique Dorlhiac Llacer
Overview
Explore the profile of Pedro Enrique Dorlhiac Llacer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hughes T, Lipton J, Spector N, Cervantes F, Pasquini R, Clementino N, et al.
Blood
. 2014 Jun;
124(5):729-36.
PMID: 24948656
Patients in complete cytogenetic response (CCyR) with detectable BCR-ABL1 after ≥2 years on imatinib were randomized to nilotinib (400 mg twice daily, n = 104) or continued imatinib (n =...
2.
Boszczowski I, Prado G, Dalben M, Telles R, Freire M, Guimaraes T, et al.
Rev Inst Med Trop Sao Paulo
. 2014 Feb;
56(1):71-6.
PMID: 24553612
Aim: The objective was to describe an outbreak of bloodstream infections by Burkholderia cepacia complex (Bcc) in bone marrow transplant and hematology outpatients. Methods: On February 15, 2008 a Bcc...
3.
Shah N, Kim D, Kantarjian H, Rousselot P, Dorlhiac Llacer P, Enrico A, et al.
Haematologica
. 2010 Feb;
95(2):232-40.
PMID: 20139391
Background: Dasatinib 100 mg once daily achieves intermittent BCR-ABL kinase inhibition and is approved for chronic-phase chronic myeloid leukemia patients resistant or intolerant to imatinib. To better assess durability of...